Cost-effectiveness of parenteral artesunate for treating children with severe malaria in sub-Saharan Africa
Yoel Lubell, Arthorn Riewpaiboon, Arjen M Dondorp, Lorenz von Seidlein, Olugbenga A Mokuolu, Margaret Nansumba, Samwel Gesase, Alison Kent, George Mtove, Rasaq Olaosebikan, Wirichada Pan Ngum, Caterina I Fanello, Ilse Hendriksen, Nicholas PJ Day, Nicholas J White & Shunmay Yeung
Volume 89, Number 7, July 2011, 504-512
Table 6. Hospital admissions for severe malaria and impact on hospital budgets of switching from parenteral quinine to artesunate to treat severe malaria in childen
|Paremeter||United Republic of Tanzania
||Mbarara, Uganda||Ilorin, Nigeria|
|Patients admitted with severe malaria per year (No.)||555||169||584||708|
|Annual cost of switching to artesunate including hotel costs (US$)a||699||−271||526||16 142|
|Annual cost of switching to artesunate excluding hotel costs (US$) b||755||−509||876||3894|
US$, United States dollar.
a Overhead costs for inpatient care as estimated in the WHO-CHOICE database.
b Only direct expenditure that will be affected by switching from quinine to artesunate.